A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Status:
Recruiting
Trial end date:
2022-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this trial is to assess the efficacy and safety of CAM2029 in patients with
acromegaly. Patients will be randomized to either CAM2029 or placebo administered
subcutaneously once monthly during 6 months.